Nextcure presents preclinical data on nc181, a novel therapeutic candidate targeting apoe4, for the treatment of alzheimer's disease

Beltsville, md., sept. 26, 2023 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, including neuroinflammatory disease, today announced the presentation of preclinical data relating to nc181, a novel humanized antibody targeting apoe4, for the treatment of alzheimer's disease (ad), at the 2nd annual neurodegeneration targets, drug discovery for progressive central nervous system disorders conference.
NXTC Ratings Summary
NXTC Quant Ranking